California's insulin initiative is an ill-conceived idea, says analyst
According to a Sydbank analyst, the state’s intention to produce insulin also shouldn’t be viewed as potential competition for makers of the drug like Novo Nordisk.
by marketwire, translated by daniel pedersen
Although California is intending to produce insulin for its own population, efforts to meet demand will hardly be a match for the big drugmakers already supplying the state, says Sydbank analyst Søren Løntoft Hansen. In all likelihood, the end product would be both more expensive and based on older research.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sanofi reduces US insulin prices for the uninsured
For subscribers
US Senators introduce bill to cap insulin prices
For subscribers
.jpg)
.jpg&w=384&q=75)
